TriangleHEALTH PROFESSIONAL · SOURCE READING
Entrectinib
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Entrectinib is a potent small-molecule inhibitor of the TRKA, TRKB, TRKC, ROS1, and ALK proteins.
Evidence (entrectinib):
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
Source links and citations
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
The objective response rate was 57% (95% CI, 34.2%−70.8%). Seven percent of patients had a complete response, and 50% of patients had a partial response.[41][Level of evidence C2]
Source links and citations
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
The median duration of response was 10 months (95% CI, 7.1−NE), and the median PFS was 11 months (95% CI, 8−14.9).
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
For the five patients with thyroid cancer, the overall response rate was 20% (95% CI, 1%−72%).
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
In the overall safety population (n = 355), the most frequently reported treatment-related adverse events were dysgeusia (41%), fatigue (28%), dizziness (26%), constipation (23%), and diarrhea (22%).
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41] › In the overall safety population (n = 355), the most frequently reported treatment-related adverse events were dysgeusia (41%), fatigue (28%), dizziness (26%), constipation (23%), and diarrhea (22%).
The most common grade 3 or 4 treatment-related adverse events were increased weight (5%) and anemia (5%).
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice